{"id":"ctiv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"cTIV uses recombinant DNA technology to produce influenza hemagglutinin antigens from four influenza virus strains (two A subtypes and two B lineages). This approach aims to improve upon traditional egg-based or cell-based flu vaccines by enabling faster manufacturing, potentially higher antigen yields, and more consistent immunogenicity across diverse populations.","oneSentence":"cTIV is a recombinant tetravalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:07.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT00310804","phase":"PHASE3","title":"Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-09","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00306527","phase":"PHASE3","title":"Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-09","conditions":"Influenza","enrollment":2235},{"nctId":"NCT02258178","phase":"","title":"Flucelvax Pregnancy Registry","status":"WITHDRAWN","sponsor":"Seqirus","startDate":"2014-09","conditions":"Pregnant Women, Influenza","enrollment":""},{"nctId":"NCT00264576","phase":"PHASE2","title":"Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-10","conditions":"Influenza Disease; Flu","enrollment":613},{"nctId":"NCT00579345","phase":"PHASE3","title":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":1522},{"nctId":"NCT00560066","phase":"PHASE4","title":"Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Seasonal Influenza, Vaccine","enrollment":1398},{"nctId":"NCT00492063","phase":"PHASE3","title":"Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Influenza","enrollment":2654},{"nctId":"NCT00645411","phase":"PHASE2, PHASE3","title":"Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":3604},{"nctId":"NCT01561768","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-03","conditions":"Influenza","enrollment":500},{"nctId":"NCT00511914","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Seasonal Influenza Vaccine","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cTIV","genericName":"cTIV","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"cTIV is a recombinant tetravalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza virus strains. Used for Seasonal influenza prevention in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}